10-Q · May 15, 2026
Sensei Biotherapeutics reported significant losses in Q1 2026, reflecting a net loss of $170.2 million, primarily from the acquisition of Faeth Therapeutics, which added $133 million in acquired in-process R&D expenses.…
Earnings analysis · 10-K
SNSE earnings analysis
Filed June 2, 2026 · Our reading of the company's report
The latest report
Sensei Biotherapeutics is focusing on developing cancer therapies using multi-node inhibition strategies following their acquisition of Faeth Therapeutics, which introduced the promising lead asset PIKTOR targeting…
Read full summary
Sensei Biotherapeutics is focusing on developing cancer therapies using multi-node inhibition strategies following their acquisition of Faeth Therapeutics, which introduced the promising lead asset PIKTOR targeting critical cancer pathways. Financially, the company has not generated revenue and has posted significant losses, with EPS reported at -131.45 in Q1 2026 and operational challenges evident in substantial yearly net losses attributed mainly to R&D expenses.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-3.74
What stood out
-
Strategic Acquisition Enhances Pipeline
The acquisition of Faeth Therapeutics enables access to the promising lead asset PIKTOR, a multi-node inhibitor targeting the PI3K/AKT/mTOR pathway.
-
Ongoing Clinical Trials for PIKTOR
Current trials for PIKTOR in advanced endometrial cancer and HR+/HER2- breast cancer are crucial steps with data expected in 2026 and 2027.
-
Potential Market Opportunity
The addressable market for the targeted indications is estimated at $6 billion in the U.S., primarily from HR+/HER2- breast cancer and endometrial cancer.
What to watch
-
Significant Operational Losses
Sensei reported a net loss of approximately $170.2 million in Q1 2026, primarily from R&D expenses, raising liquidity concerns.
-
Zero Revenue Generation
The company has continued to report zero revenue, indicating severe operational difficulties or feasibility issues.
-
High Financial Burden from Acquisition
The acquisition of Faeth, while strategic, has added substantial debts and liabilities which could strain future financial performance.
Management's outlook
No forward guidance provided; additional metrics likely discussed in earnings calls.
Earlier filings 4
10-K · March 30, 2026
Sensei completed the acquisition of Faeth Therapeutics on February 17, 2026 and received $200.0 million in gross proceeds from a 2026 private placement to advance Faeth’s lead asset, PIKTOR. PIKTOR is now the company's…
10-Q · November 14, 2025
Sensei reported a Q3 2025 net loss per share of $(3.62), an improvement from $(5.77) in Q3 2024 and from $(3.91) in Q2 2025. Operating expenses declined to $4,851,000 in Q3 2025 from $7,823,000 in Q3 2024, but the…
10-K · March 28, 2025
Sensei Biotherapeutics positions itself as a tumor-microenvironment–focused biotech developing pH-selective antibodies from its TMAb platform, with solnerstotug (SNS-101) as the lead asset. The company reported…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.